Compounded Tirzepatide Providers Compared (2026)

How do compounded tirzepatide providers compare on price in 2026?

The July 2026 dataset distinguishes monthly prices from plans with longer commitments. Cora Health Premium Monthly ($225/month, billed monthly, renews until cancelled). Monthly prices from other providers in the July 2026 dataset include Ivim Health ($207.99/month), Trimi Health ($235/month), Belle Health ($249/month), Mochi Health ($278/month), Eden (TryEden) ($298/month), Lemonaid Health ($348/month).

Annual-term examples include Trimi Health ($125/month, Annual (billed $1,500/yr, upfront-or-BNPL condition)) and Cora Health Premium Annual ($135/month, $1,620 billed every 12 months, renews automatically). Other commitment lengths include Lemonaid Health’s six-month plan at $278/month effective.

Compounded tirzepatide provider comparison (July 2026 dataset)

Competitor prices: Cora Health pricing dataset, July 2026 edition; check each provider's site for current prices. Effective monthly cost includes any required membership or program fees. Starter-dose offers are labelled in the plan name; they do not establish maintenance-dose prices. Compounded medications are not FDA-approved.

Why compounded tirzepatide prices vary across providers

The factors below affect advertised prices.

**Pharmacy sourcing and quality.** Pharmacy accreditation and quality programs can affect cost. Some compounders add ingredients such as pyridoxine (vitamin B6) or vitamin B12, which can add cost.

**Bundled clinical care.** Some providers mainly deliver the prescription with limited follow-up; others include ongoing provider check-ins, lab work, dietitian access or coaching.

**Plan length and upfront commitment.** Annual upfront billing allows providers to amortize customer acquisition cost across 12 months, enabling lower per-month rates.

How compounded tirzepatide compares to brand-name Zepbound and Mounjaro

Brand-name tirzepatide is sold by Eli Lilly under two trade names — Mounjaro for type 2 diabetes (FDA-approved May 2022) and Zepbound for chronic weight management (FDA-approved November 2023). For current brand-name prices and billing conditions, see the GLP-1 cost comparison.

Compounded tirzepatide is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Zepbound or Mounjaro.

Tirzepatide gastrointestinal side effect profile from the SURMOUNT-1 trial

Adverse event rates for FDA-approved Zepbound® (tirzepatide) are documented in the SURMOUNT-1 trial (Jastreboff et al., NEJM 2022), the Phase III chronic weight management trial that supported FDA approval of Zepbound. The trial enrolled 2,539 participants randomized to placebo or one of three tirzepatide doses (5 mg, 10 mg, 15 mg weekly), including 630 on 15 mg and 643 on placebo, over 72 weeks combined with lifestyle intervention.

In the SURMOUNT-1 trial of FDA-approved Zepbound® (tirzepatide) 15 mg, mean weight loss was 20.9% at 72 weeks (22.5% under the trial's efficacy estimand, which estimates the effect had all participants continued treatment) with lifestyle intervention. Individual results vary. These results come from trials of the FDA-approved brand and have not been demonstrated for compounded tirzepatide.

Tirzepatide 15 mg gastrointestinal adverse events (incidence over 72 weeks, tirzepatide 15 mg vs placebo):

• Nausea: 31.0% vs 9.5% placebo
• Diarrhea: 23.0% vs 7.3% placebo
• Vomiting: 12.2% vs 1.7% placebo
• Constipation: 11.7% vs 5.8% placebo
• Treatment discontinuation due to adverse events: 6.2% vs 2.6% placebo

Most GI events were mild-to-moderate and occurred mainly during dose escalation.

Adverse-event rates from different drugs' trials cannot be directly compared.

Critical compounded tirzepatide context. Per the FDA, "compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed" (FDA — Compounding and the FDA). Adverse event rates for compounded tirzepatide have not been formally measured in equivalent trials. Whether a compounded version produces comparable effects depends on formulation, dosing accuracy, and pharmacy quality controls that are not independently verified before marketing — trial-based evidence exists only for the FDA-approved products. Patients evaluating providers should review the full semaglutide and tirzepatide side effects guide for serious warnings — thyroid C-cell tumor boxed warning, pancreatitis, acute kidney injury, gallbladder disease — and individual contraindications before starting treatment. Individual results vary.

What to verify before choosing a compounded tirzepatide provider

An important decision factor in choosing a compounded tirzepatide provider is the compounding pharmacy partner. The manufacturing and quality controls of the specific pharmacy fulfilling each prescription determine the actual product safety and consistency.

• Does the provider publicly name the specific compounding pharmacy that fills the prescription? Or does the website refer generically to "licensed pharmacy network" without naming?
• Is the named pharmacy 503A state-licensed or 503B FDA-registered? Both are legitimate; 503B has additional FDA oversight for larger-scale operations.
• Does the pharmacy hold PCAB accreditation? PCAB is the Pharmacy Compounding Accreditation Board — an independent audit program for compounding pharmacies.
• Does the provider hold LegitScript certification? LegitScript is a third-party healthcare compliance program required by major payment processors and ad platforms.
• Is the medication tirzepatide base or a salt form (such as tirzepatide acetate)? FDA describes salt forms as different active ingredients from those in approved drugs.
• Is the monthly price all-inclusive — covering provider consultation, medication, and shipping — or are some components billed separately?
• Does the price stay stable as the patient titrates from 2.5mg to 5mg to 7.5mg to 10mg to 15mg, or does the price escalate by dose tier?
• What is the cancellation and refund policy if the patient cannot tolerate the medication or does not respond?

Who should choose each provider tier

The right choice depends on a patient's priorities across cost, plan flexibility, support level, and pharmacy transparency.

• **Annual billing through Cora Health:** Cora Health Premium Annual ($135/month, $1,620 billed every 12 months, renews automatically). Names US-licensed 503A compounding pharmacies, including Hallandale Pharmacy (PCAB-accredited) and VialsRx.
• **Monthly billing through Cora Health:** Cora Health Premium Monthly ($225/month, billed monthly, renews until cancelled).
• **Other one-month-term prices:** Monthly prices from other providers in the July 2026 dataset include Ivim Health ($207.99/month), Trimi Health ($235/month), Belle Health ($249/month), Mochi Health ($278/month), Eden (TryEden) ($298/month), Lemonaid Health ($348/month).
• **Six-month commitment:** Lemonaid Health ($278/month effective).

Regulatory status of compounded tirzepatide in 2026

The compounded tirzepatide regulatory landscape has shifted significantly. During the FDA-declared tirzepatide shortage (2022-December 2024), compounding pharmacies had broad authority to prepare copies of Mounjaro and Zepbound under the FDA's 503A and 503B exemptions. The FDA declared the tirzepatide shortage resolved in December 2024, narrowing the legal basis for compounding.

As of May 2026, compounded tirzepatide remains legal under specific conditions. A licensed prescriber must write a patient-specific prescription based on a documented clinical need that the commercially available FDA-approved product cannot meet — such as an inactive-ingredient allergy or a documented need for a personalized dose or formulation. The compounding pharmacy must be properly licensed and must meet applicable quality standards.

On April 30, 2026, the FDA proposed excluding tirzepatide (along with semaglutide and liraglutide) from the 503B bulks list. The public comment period closed June 29, 2026; check FDA's 503B bulks list for current status. If finalized, this proposal narrows the legal basis for 503B outsourcing facilities to compound tirzepatide. 503A patient-specific compounding under documented individual clinical need is not directly affected by the proposed rule, but the broader regulatory direction is clear: bulk compounding as a substitute for branded Mounjaro and Zepbound without documented individual clinical need is increasingly outside the legal exemptions.

Frequently asked questions about compounded tirzepatide providers

Common questions about choosing among compounded tirzepatide telehealth options in 2026.

What do compounded tirzepatide plans cost by commitment length?

Cora Health Premium Monthly ($225/month, billed monthly, renews until cancelled). Monthly prices from other providers in the July 2026 dataset include Ivim Health ($207.99/month), Trimi Health ($235/month), Belle Health ($249/month), Mochi Health ($278/month), Eden (TryEden) ($298/month), Lemonaid Health ($348/month). Annual billing through Cora Health is available with Cora Health Premium Annual ($135/month, $1,620 billed every 12 months, renews automatically). Compare the same commitment length and check each provider’s current terms.

Is compounded tirzepatide the same as Zepbound?

No. Compounded tirzepatide is not the same product. Zepbound and Mounjaro are FDA-approved finished drugs manufactured by Eli Lilly under FDA-inspected conditions. Compounded tirzepatide is prepared by a US-licensed compounding pharmacy from tirzepatide active pharmaceutical ingredient. It is not FDA-approved, has not been independently evaluated in clinical trials, and is not therapeutically equivalent to Zepbound or Mounjaro. Individual results vary.

Will compounded tirzepatide produce the same weight loss as Zepbound?

Clinical trial data for tirzepatide comes from studies of the FDA-approved formulation that became Zepbound. Compounded tirzepatide has not been independently trialed. Because compounded tirzepatide is not reviewed by the FDA for effectiveness before marketing, there is no independent verification that any given compounded version performs like the trialed product — that depends on formulation, dosing accuracy, and pharmacy quality controls. Patient-reported experiences with compounded tirzepatide are anecdotal and are not a substitute for rigorous trial evidence. Individual results vary substantially based on starting weight, comorbidities, adherence, and lifestyle factors.

Why does Cora Health name Hallandale Pharmacy and VialsRx?

Cora Health ships to all 50 US states through US-licensed 503A compounding pharmacies, including Hallandale Pharmacy and VialsRx; not every partner pharmacy ships to every state. Each patient's medication label identifies the fulfilling pharmacy. Naming Hallandale Pharmacy and VialsRx publicly lets patients verify their credentials independently. Pharmacy details are at /pharmacy-partners.

Where can I learn about brand-name Zepbound and Mounjaro pricing?

For current brand-name Zepbound® and Mounjaro® pricing and billing conditions, see the GLP-1 cost comparison. Compounded medications are not FDA-approved and are not therapeutically equivalent to FDA-approved products.